scholarly journals Foot process fusion and glomerular filtration rate in minimal change nephrotic syndrome

1984 ◽  
Vol 25 (4) ◽  
pp. 696-700 ◽  
Author(s):  
Sven-Olof Bohman ◽  
Georg Jaremko ◽  
Ann-Britt Bohlin ◽  
Ulla Berg
1994 ◽  
Vol 8 (4) ◽  
pp. 404-407 ◽  
Author(s):  
Sally-Anne Hulton ◽  
Lyda Jadresic ◽  
Vanita Shah ◽  
Richard S. Trompeter ◽  
Michael J. Dillon ◽  
...  

1985 ◽  
Vol 19 (4) ◽  
pp. 376A-376A
Author(s):  
Michael Freundllch ◽  
Jacques J Bourgolgnie ◽  
Gaston Zllleruelo ◽  
Carolyn Ahithol ◽  
Jose Strauss

2019 ◽  
Vol 2019 ◽  
pp. 1-8
Author(s):  
Akihiro Tojo

As water and solutes are filtered through the slit membrane, it is an a priori concept that a slit membrane is an essential filtration barrier for proteins, including albumin. However, in cases of minimal change nephrotic syndrome, the number of slit membranes is reduced by the foot process effacement and tight junction-like cell adhesion. Furthermore, albumin endocytosis is enhanced in the podocytes under condition of minimal change disease, and albumin is selectively transported by the albumin receptor FcRn. Suppressing the endocytosis of albumin with anti-FcRn antibody decreases the urinary protein level. The expression of motor molecules, such as cytoplasmic dynein 1 and myosin IX, is increased in the podocytes under conditions of minimal change nephrotic syndrome, suggesting the enhanced transport of vesicles containing albumin. Podocyte vesicle transport may play an important role in the pathology of selective albuminuria in cases of nephrotic syndrome.


1992 ◽  
Vol 82 (6) ◽  
pp. 641-650 ◽  
Author(s):  
Robert Zietse ◽  
Gerrit J. Wenting ◽  
Pieter Kramer ◽  
Maarten A. Schalekamp ◽  
Willem Weimar

1. To elucidate the mechanisms by which cyclosporin A diminishes proteinuria, we studied 20 patients with severe nephrotic syndrome. Biopsy-established pathologies included minimal change disease (n = 5), membranous glomerulopathy (n = 6), membranoproliferative glomerulonephritis (n = 5) and focal segmental glomerulosclerosis (n = 4). Before, at the end of a 90 day course of cyclosporin A, and finally 1 month after stopping cyclosporin A we determined 24 h protein excretion. Measurements of glomerular filtration rate, effective renal plasma flow, fractional clearance rates of albumin and immunoglobulins with different charges and the transglomerular sieving of uncharged dextrans of broad size distribution were used to study the effects of cyclosporin A on renal perfusion and the glomerular filtration barrier. The findings were analysed with a theoretical model of solute transport. 2. Among the different forms of glomerulopathy the response to low-dose cyclosporin A (trough levels 32.0–36.9 ng/ml) varied markedly. In minimal change disease, proteinuria decreased from 9.5 ± 3.1 to 1.3 ± 0.2 g/24 h (mean ± sem, P < 0.01). This response was due to restoration of the charge selectivity of the glomerular barrier. The depressed value of the glomerular permeability coefficient also returned to normal. Glomerular filtration rate, effective renal plasma flow and renal vascular resistance did not change. Proteinuria returned after stopping cyclosporin A, although it did not reach pretreatment levels. In membranous glomerulopathy, proteinuria fell from 9.9 ± 1.5 to 1.8 ± 0.3 g/24 h (P < 0.01). Changes in protein excretion and dextran sieving were compatible with an increase in glomerular permselectivity and a decrease in filtrate flow through the ‘shunt’ pathway. Glomerular filtration rate was maintained, although effective renal plasma flow fell significantly. Proteinuria relapsed after stopping cyclosporin A. In membranoproliferative glomerulonephritis and focal segmental glomerulosclerosis proteinuria did not respond to cyclosporin A, although cyclosporin A exerted important haemodynamic effects. 3. In minimal change disease and membranous glomerulopathy cyclosporin A exerts its beneficial effects on proteinuria through changes in the properties of the glomerular barrier, resulting in increased charge and size selectivity, respectively.


2017 ◽  
Vol 4 ◽  
pp. 205435811770949
Author(s):  
Sulaiman Alsaidi ◽  
Daniel Wagner ◽  
Silviu Grisaru ◽  
Julian Midgley ◽  
Lorraine Hamiwka ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document